1
|
Djaafri I, Khayati F, Menashi S, Tost J, Podgorniak MP, Sadoux A, Daunay A, Teixeira L, Soulier J, Idbaih A, Setterblad N, Fauvel F, Calvo F, Janin A, Lebbé C, Mourah S. A novel tumor suppressor function of Kindlin-3 in solid cancer. Oncotarget 2015; 5:8970-85. [PMID: 25344860 PMCID: PMC4253411 DOI: 10.18632/oncotarget.2125] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Kindlin-3 (FERMT-3) is known to be central in hemostasis and thrombosis control and its deficiency disrupts platelet aggregation and causes Leukocyte Adhesion Deficiency disease. Here we report that Kindlin-3 has a tumor suppressive role in solid cancer. Our present genetic and functional data show that Kindlin-3 is downregulated in several solid tumors by a mechanism involving gene hypermethylation and deletions. In vivo experiments demonstrated that Kindlin-3 knockdown in 2 tumor cell models (breast cancer and melanoma) markedly increases metastasis formation, in accord with the in vitro increase of tumor cell malignant properties. The metastatic phenotype was supported by a mechanism involving alteration in β3-integrin activation including decreased phosphorylation, interaction with talin and the internalization of its active form leading to less cell attachment and more migration/invasion. These data uncover a novel and unexpected tumor suppressor role of Kindin-3 which can influence integrins targeted therapies development.
Collapse
Affiliation(s)
- Ibtissem Djaafri
- Inserm UMR-S 940 Paris, France. Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
| | - Farah Khayati
- Inserm UMR-S 940 Paris, France. Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. AP-HP, Hôpital Saint-Louis, Laboratoire de Pharmacologie-Génétique, Paris, France
| | | | - Jorg Tost
- Laboratory for Epigenetics, Centre National de Génotypage, CEA-Institut de Génomique, Evry, France. Laboratory for Functional Genomics, Fondation Jean Dausset - CEPH, Paris, France
| | | | - Aurelie Sadoux
- Inserm UMR-S 940 Paris, France. AP-HP, Hôpital Saint-Louis, Laboratoire de Pharmacologie-Génétique, Paris, France
| | - Antoine Daunay
- Laboratory for Functional Genomics, Fondation Jean Dausset - CEPH, Paris, France
| | - Luis Teixeira
- AP-HP, Hôpital Saint-Louis, Service d'oncologie médicale, Paris, France
| | - Jean Soulier
- Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Hematology Laboratory APHP, Saint-Louis Hospital, Paris, France
| | - Ahmed Idbaih
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France. Inserm U 975, Paris, 75013 France, CNRS, UMR, Paris, France
| | - Niclas Setterblad
- Inserm UMR-S 940 Paris, France. Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
| | - Françoise Fauvel
- Inserm UMR-S 940 Paris, France. Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
| | - Fabien Calvo
- Inserm UMR-S 940 Paris, France. Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
| | - Anne Janin
- Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Inserm, U728, Paris, France. AP-HP, Hôpital Saint-Louis, Laboratoire de Pathologie, Paris, France
| | - Celeste Lebbé
- Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. AP-HP, Hôpital Saint-Louis, Département de Dermatologie, Paris, France. Inserm U976, Paris, France
| | - Samia Mourah
- Inserm UMR-S 940 Paris, France. Institute of Hematology (IUH), Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
2
|
Deckmyn H, De Meyer SF, Broos K, Vanhoorelbeke K. Inhibitors of the interactions between collagen and its receptors on platelets. Handb Exp Pharmacol 2012:311-337. [PMID: 22918737 DOI: 10.1007/978-3-642-29423-5_13] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
At sites of vascular injury, collagen-mediated platelet adhesion and activation have long been known as one of the first events in platelet-dependent thrombus formation. Studying patients with bleeding disorders that are caused by defective platelet adhesion to collagen resulted in the identification of several platelet collagen receptors, with glycoprotein VI and integrin α2β1 being the most important ones. Subsequent development of specific collagen receptor knockout mice and various inhibitors of platelet binding to collagen have further proven the role of these receptors in haemostasis and thrombosis. The search for clinically applicable inhibitors for use as antithrombotic drug has led to the identification of inhibitory antibodies, soluble receptor fragments, peptides, collagen-mimetics and proteins from snake venoms or haematophagous animals. In experimental settings, these inhibitors have a good antithrombotic effect, with little prolongation of bleeding times, suggesting a larger therapeutic window than currently available antiplatelet drugs. However, at present, none of the collagen receptor blockers are in clinical development yet.
Collapse
Affiliation(s)
- Hans Deckmyn
- Laboratory for Thrombosis Research, KU Leuven campus Kortrijk, Kortrijk, Belgium.
| | | | | | | |
Collapse
|